# A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma

> **NCT00931840** · PHASE2 · UNKNOWN · sponsor: **Enzon Pharmaceuticals, Inc.** · enrollment: 220 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** EZN-2208, Cetuximab and Irinotecan

## Key facts

- **NCT ID:** NCT00931840
- **Lead sponsor:** Enzon Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2009-06
- **Primary completion:** 2011-10
- **Final completion:** 2012-01
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2011-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00931840

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00931840, "A Study of EZN-2208 Administered With or Without Cetuximab in Patients With Metastatic Colorectal Carcinoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00931840. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*